Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Cephalon, Inc.
Among other Asia deals, Takeda adds to pair of recent gene therapy tie-ups with a CNS-focused cell therapy partnership with Immusoft; earlier it licensed ex-US rights to JCR’s Hunter syndrome drug.
Chinese venture Brii seeks US emergency authorization for its antibody combo, as Chugai aims for wider use of its antibody cocktail in Japan and two other Chinese firms link up on an oral antiviral.
Building upon the May 2020 acquisition of US WorldMeds, Supernus is diversifying beyond Trokendi for epilepsy and will be able to rely on its existing commercial force for CNS products.
The oncologic drugs advisory committee’s upcoming reviews are moving beyond the PD-1/PDL-1 inhibitor class – and to a very different type of sponsor.
- Other Names / Subsidiaries
- Arana Therapeutics (Peptech and EvoGenix)
- BioAssets Development Corporation
- Ception Therapeutics
- ChemGenex Pharmaceuticals Limited
- CIMA Labs
- Gemin X Pharmaceuticals
- Zeneus Pharma